Sophiris Bio Inc. (SHS.TO), headquartered in San Diego, California, is a publicly traded biopharmaceutical company focused on urology. Sophiris’s lead program is a novel 15-minute outpatient procedure for treating men with Benign Prostatic Hyperplasia (“BPH”). The procedure is administered by a urologist and involves injecting a proprietary drug called PRX-302 directly into the prostate. In a double-blind, randomized, placebo-controlled Phase IIb study in Canada, PRX-302 appeared to offer superior efficacy to oral drugs and demonstrated a benign safety profile. The Company, formerly known as Protox Therapeutics Inc., is developing PRX-302 for the US market where it is currently in Phase II development.
Back to Previous Page